JP2014534233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534233A5 JP2014534233A5 JP2014540611A JP2014540611A JP2014534233A5 JP 2014534233 A5 JP2014534233 A5 JP 2014534233A5 JP 2014540611 A JP2014540611 A JP 2014540611A JP 2014540611 A JP2014540611 A JP 2014540611A JP 2014534233 A5 JP2014534233 A5 JP 2014534233A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 13
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 239000002254 cytotoxic agent Substances 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 231100000599 cytotoxic agent Toxicity 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- KAHJVVNKEWQPJI-JXJGXUGVSA-N (2S)-2-acetamido-6-aminohexanoic acid (2S)-2-amino-3-methylbutanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC(=O)N[C@@H](CCCCN)C(O)=O KAHJVVNKEWQPJI-JXJGXUGVSA-N 0.000 claims 1
- -1 1,3-thiazol-2-yl Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims 1
- 229920001222 biopolymer Polymers 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000005443 oral cavity cancer Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Images
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559015P | 2011-11-11 | 2011-11-11 | |
| US61/559,015 | 2011-11-11 | ||
| US201261640641P | 2012-04-30 | 2012-04-30 | |
| US61/640,641 | 2012-04-30 | ||
| US201261717288P | 2012-10-23 | 2012-10-23 | |
| US61/717,288 | 2012-10-23 | ||
| PCT/IB2012/056234 WO2013068946A2 (en) | 2011-11-11 | 2012-11-07 | Antibodies specific for trop-2 and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240754A Division JP6157575B2 (ja) | 2011-11-11 | 2015-12-10 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534233A JP2014534233A (ja) | 2014-12-18 |
| JP2014534233A5 true JP2014534233A5 (enExample) | 2015-02-05 |
| JP5936702B2 JP5936702B2 (ja) | 2016-06-22 |
Family
ID=47216378
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014540611A Expired - Fee Related JP5936702B2 (ja) | 2011-11-11 | 2012-11-07 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| JP2015240754A Expired - Fee Related JP6157575B2 (ja) | 2011-11-11 | 2015-12-10 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| JP2017049125A Expired - Fee Related JP6475277B2 (ja) | 2011-11-11 | 2017-03-14 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015240754A Expired - Fee Related JP6157575B2 (ja) | 2011-11-11 | 2015-12-10 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
| JP2017049125A Expired - Fee Related JP6475277B2 (ja) | 2011-11-11 | 2017-03-14 | Ｔｒｏｐ−２に対して特異的な抗体およびこれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8871908B2 (enExample) |
| EP (1) | EP2776470A2 (enExample) |
| JP (3) | JP5936702B2 (enExample) |
| KR (1) | KR20140091040A (enExample) |
| CN (1) | CN104053672A (enExample) |
| AR (1) | AR088693A1 (enExample) |
| AU (1) | AU2012335205A1 (enExample) |
| BR (1) | BR112014011331A2 (enExample) |
| CA (2) | CA2954166A1 (enExample) |
| CO (1) | CO7010785A2 (enExample) |
| HK (1) | HK1201851A1 (enExample) |
| IL (1) | IL232426A0 (enExample) |
| MX (1) | MX2014005728A (enExample) |
| PH (1) | PH12014500932A1 (enExample) |
| RU (1) | RU2014116406A (enExample) |
| SA (1) | SA112330988B1 (enExample) |
| SG (1) | SG11201401699WA (enExample) |
| TW (1) | TWI495644B (enExample) |
| WO (1) | WO2013068946A2 (enExample) |
| ZA (1) | ZA201403492B (enExample) |
Families Citing this family (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8435529B2 (en) | 2002-06-14 | 2013-05-07 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
| AR088693A1 (es) * | 2011-11-11 | 2014-06-25 | Rinat Neuroscience Corp | Anticuerpos especificos para trop-2 y sus usos |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| US10132799B2 (en) | 2012-07-13 | 2018-11-20 | Innate Pharma | Screening of conjugated antibodies |
| IL294622B2 (en) | 2012-10-11 | 2023-10-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugates and methods for their preparation |
| CA2890569C (en) | 2012-11-05 | 2019-03-05 | Pfizer Inc. | Spliceostatin analogs |
| US10036010B2 (en) | 2012-11-09 | 2018-07-31 | Innate Pharma | Recognition tags for TGase-mediated conjugation |
| US20240139324A1 (en) | 2012-12-13 | 2024-05-02 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| AU2013360335B2 (en) | 2012-12-13 | 2017-12-07 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| BR112015030514A2 (pt) | 2013-06-04 | 2017-08-29 | Cytomx Therapeutics Inc | Composições e métodos para conjugação de anticorpos ativáveis |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN105517577A (zh) * | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| WO2015015448A2 (en) * | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| DK3424955T3 (da) | 2013-12-25 | 2025-06-16 | Daiichi Sankyo Co Ltd | Fremgangsmåde til fremstilling af anti-trop2 antistof-lægemiddelkonjugat |
| AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| KR101871088B1 (ko) | 2014-01-27 | 2018-06-25 | 화이자 인코포레이티드 | 이관능성 세포독성제 |
| EP4212552B1 (en) | 2014-01-31 | 2024-11-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| EP3107577B1 (en) | 2014-02-21 | 2024-03-20 | IBC Pharmaceuticals, Inc. | Disease therapy by inducing immune response to trop-2 expressing cells |
| US11602525B2 (en) * | 2014-04-25 | 2023-03-14 | Rinat Neuroscience Corp. | Antibody-drug conjugates with high drug loading |
| HRP20210292T1 (hr) * | 2014-04-30 | 2021-04-16 | Pfizer Inc. | Anti-ptk7 protutijelo-lijek konjugati |
| WO2015191883A1 (en) * | 2014-06-12 | 2015-12-17 | Dophen Biomedical | Homogenous antibody drug conjugates via enzymatic methods |
| SI3185908T1 (sl) | 2014-08-28 | 2020-08-31 | Pfizer Inc. | Linkerji za modulacijo stabilnosti, ki se uporabljajo s konjugati zdravil s protitelesi |
| JP2018500930A (ja) | 2014-12-04 | 2018-01-18 | アブルッツォ・セラノスティックス・エッセ・エッレ・エッレ | ヒト化抗ｔｒｏｐ−２モノクローナル抗体及びその使用 |
| BR112017018706B1 (pt) | 2015-03-20 | 2023-01-24 | Pfizer Inc | Agentes citotóxicos bifuncionais contendo o farmacoforo cti, composição farmacêutica e uso dos mesmos |
| US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CN106554420A (zh) * | 2015-09-30 | 2017-04-05 | 上海众合医药科技股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| TWI726942B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| TWI703160B (zh) * | 2015-11-30 | 2020-09-01 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JP2018058822A (ja) | 2016-08-03 | 2018-04-12 | ファイザー・インク | ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用 |
| WO2018036438A1 (zh) * | 2016-08-23 | 2018-03-01 | 四川科伦博泰生物医药股份有限公司 | 一种抗体-药物偶联物及其制备方法和应用 |
| CN116143678A (zh) | 2016-11-14 | 2023-05-23 | 杭州多禧生物科技有限公司 | 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
| JPWO2018110515A1 (ja) | 2016-12-12 | 2019-10-24 | 第一三共株式会社 | 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ |
| BR112019012847A2 (pt) | 2017-01-17 | 2019-12-10 | Daiichi Sankyo Co Ltd | anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor. |
| BR112019015069A2 (pt) | 2017-01-24 | 2020-03-03 | Pfizer Inc. | Derivados de caliqueamicina e conjugados de anticorpo-fármaco dos mesmos |
| EP3600283A4 (en) | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR |
| CA3058966A1 (en) | 2017-04-14 | 2018-10-18 | Tollnine, Inc. | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use |
| IL270415B2 (en) | 2017-05-12 | 2024-08-01 | Crispr Therapeutics Ag | Materials and methods for cell engineering and their uses in immuno-oncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| TW202542161A (zh) | 2017-05-15 | 2025-11-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| EP3625253A4 (en) | 2017-05-16 | 2021-03-24 | Scalmibio, Inc. | ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE |
| CN107446050A (zh) * | 2017-08-11 | 2017-12-08 | 百奥泰生物科技(广州)有限公司 | Trop2阳性疾病治疗的化合物及方法 |
| AU2018327171B2 (en) | 2017-08-31 | 2023-03-09 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| JP7248578B2 (ja) | 2017-08-31 | 2023-03-29 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| WO2019215500A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| AU2019304175A1 (en) * | 2018-07-09 | 2021-03-04 | Genequantum Healthcare (Suzhou) Co., Ltd. | Antibodies specific to trophoblast antigen 2 (TROP2) |
| EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
| KR20250172902A (ko) | 2018-07-31 | 2025-12-09 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료 |
| EP3842546A4 (en) | 2018-08-23 | 2022-06-29 | Daiichi Sankyo Company, Limited | Sensitivity marker for antibody-drug conjugate |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| WO2020047473A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| WO2020094670A1 (en) | 2018-11-05 | 2020-05-14 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| US12458818B2 (en) | 2019-03-19 | 2025-11-04 | CSPC Megalith Biopharmaceutical Co., Ltd. | Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN112243443B (zh) * | 2019-05-10 | 2023-03-17 | 江苏豪森药业集团有限公司 | 抗trop-2抗体、其抗原结合片段及其医药用途 |
| TW202108180A (zh) | 2019-05-29 | 2021-03-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物的調劑 |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN114040778A (zh) | 2019-06-29 | 2022-02-11 | 杭州多禧生物科技有限公司 | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 |
| WO2021027851A1 (zh) * | 2019-08-12 | 2021-02-18 | 凯惠科技发展(上海)有限公司 | 一种trop2抗体及其制备方法、其偶联物和应用 |
| CN112646038B (zh) * | 2019-10-11 | 2025-06-03 | 迈威(上海)生物科技股份有限公司 | 抗人Trop-2抗体及其应用 |
| US20230101266A1 (en) * | 2019-12-31 | 2023-03-30 | Genequantum Healthcare (Suzhou) Co., Ltd. | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| JP2023513573A (ja) | 2020-02-11 | 2023-03-31 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢性および炎症性疾患を治療する方法 |
| CA3176095A1 (en) | 2020-03-20 | 2021-09-23 | Immunomedics, Inc. | Biomarkers for sacituzumab govitecan therapy |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| CA3176626A1 (en) | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| WO2021247604A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247908A1 (en) * | 2020-06-03 | 2021-12-09 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
| BR112022025947A2 (pt) * | 2020-06-22 | 2023-03-14 | Baili Bio Chengdu Pharmaceutical Co Ltd | Anticorpo anti-trop2, sequência de ácidos nucleicos, rna, vetor de expressão, hospedeiro, conjugado imune e usos do anticorpo |
| US20230263903A1 (en) | 2020-08-13 | 2023-08-24 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| US20230374149A1 (en) * | 2020-10-14 | 2023-11-23 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-trop-2 antibody, antigen-binding fragment thereof or mutant thereof, and medical use thereof |
| CN112321715B (zh) * | 2020-11-03 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗trop2纳米抗体及其制备方法和应用 |
| IT202000031838A1 (it) * | 2020-12-22 | 2022-06-22 | Saverio Alberti | Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici |
| CN114685669A (zh) * | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
| JP2024511088A (ja) | 2021-03-26 | 2024-03-12 | ボルト バイオセラピューティクス、インコーポレーテッド | ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用 |
| IL306114A (en) | 2021-03-26 | 2023-11-01 | Bolt Biotherapeutics Inc | 2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof |
| EP4349371A4 (en) | 2021-06-02 | 2025-06-25 | Bio-Thera Solutions, Ltd. | DRUG CONJUGATE AND USE THEREOF |
| CA3222752A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| US12227574B2 (en) | 2021-06-17 | 2025-02-18 | Amberstone Biosciences, Inc. | Anti-CD3 constructs and uses thereof |
| CN115536747B (zh) * | 2021-06-30 | 2024-08-27 | 益科思特(北京)医药科技发展有限公司 | 一种结合trop2的抗体及靶向trop2和cd3的双特异性抗体及其制备方法与应用 |
| CN115558026A (zh) * | 2021-07-02 | 2023-01-03 | 和迈生物科技有限公司 | 抗trop2单域抗体及其应用 |
| WO2023046003A1 (zh) * | 2021-09-23 | 2023-03-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其制备方法和医药用途 |
| CN118541392A (zh) * | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| CN120795159A (zh) * | 2021-12-02 | 2025-10-17 | 浙江博锐生物制药有限公司 | 抗Trop-2抗体及其用途 |
| US20250034275A1 (en) * | 2021-12-07 | 2025-01-30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Anti-trop-2 antibody or antigen-binding fragment thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4477674A1 (en) | 2022-02-09 | 2024-12-18 | Daiichi Sankyo Company, Limited | Environmentally responsive masked antibody and use thereof |
| EP4479042A1 (en) | 2022-02-18 | 2024-12-25 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
| EP4486368A1 (en) | 2022-03-02 | 2025-01-08 | ImmunityBio, Inc. | Method of treating pancreatic cancer |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| JP2025510700A (ja) | 2022-03-23 | 2025-04-15 | シンアフィックス ビー．ブイ． | Ｔｒｏｐ－２を発現する腫瘍を標的化するための抗体コンジュゲート |
| CA3256048A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING A TUMOR ANTIGEN |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024002042A1 (zh) | 2022-06-27 | 2024-01-04 | 百奥泰生物制药股份有限公司 | 治疗实体瘤的方法 |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| CN117430710B (zh) * | 2022-07-21 | 2025-07-04 | 中国医学科学院医药生物技术研究所 | 一种针对Trop2的单克隆抗体及其应用 |
| WO2024097812A1 (en) | 2022-11-04 | 2024-05-10 | Gilead Sciences, Inc. | Therapy for treating bladder cancer |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| JP2026502860A (ja) | 2022-12-23 | 2026-01-27 | ジェネンテック， インコーポレイテッド | セレブロン分解剤コンジュゲートおよびその使用 |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| JP2026506037A (ja) | 2023-02-14 | 2026-02-20 | ボルト バイオセラピューティクス、インコーポレーテッド | アザベンズアゼピンイムノコンジュゲート及びその使用 |
| WO2024186626A1 (en) | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| EP4695260A1 (en) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024261810A1 (en) | 2023-04-24 | 2025-11-13 | Merck Sharp & Dohme Llc | Trop2 binders and conjugates thereof |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024289598A1 (en) * | 2023-07-05 | 2026-01-22 | Agency For Science, Technology And Research | Anti-trop2 antibodies |
| AU2024292473A1 (en) | 2023-07-19 | 2026-01-29 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| AU2024300557A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025111445A1 (en) * | 2023-11-21 | 2025-05-30 | Convergent Therapeutics, Inc. | Trop-2 radiopharmaceutical conjugate and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025250825A1 (en) * | 2024-05-30 | 2025-12-04 | Sutro Biopharma, Inc. | Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies |
| WO2026019374A1 (en) | 2024-07-19 | 2026-01-22 | Hummingbird Bioscience Pte. Ltd. | Trop2-binding molecules |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260049118A1 (en) | 2024-08-19 | 2026-02-19 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| WO2026055185A1 (en) | 2024-09-04 | 2026-03-12 | Bolt Biotherapeutics, Inc. | Sting agonist immunoconjugates and uses thereof |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| ATE240401T1 (de) | 1989-03-21 | 2003-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU663725B2 (en) | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| ATE227979T1 (de) | 1993-04-22 | 2002-12-15 | Skyepharma Inc | Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| DK0729351T3 (da) | 1993-11-16 | 2000-10-16 | Skyepharma Inc | Vesikler med reguleret afgivelse af aktivstoffer |
| US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
| JP4303315B2 (ja) | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| JP2001501801A (ja) | 1995-10-19 | 2001-02-13 | ブリストル−マイヤーズ スクイッブ カンパニー | モノクローナル抗体ｂｒ１１０およびその使用 |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US5850854A (en) | 1997-10-02 | 1998-12-22 | Carroll; Norman Lee | Pipe closure |
| US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1151299A4 (en) * | 1999-01-22 | 2003-06-04 | Smithkline Beecham Corp | PROCESS OF LOCATION-SPECIFIC MARKING OF PROTEINS AND APPLICATIONS |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| CN102746399B (zh) | 2002-12-24 | 2016-03-02 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US20080025977A1 (en) | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| CA2604238C (en) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US20080213267A1 (en) | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) * | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2008101957A1 (en) * | 2007-02-22 | 2008-08-28 | Novo Nordisk Health Care Ag | Modulating enzymatic processes by addition of diolcontaining substances |
| CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| AR088693A1 (es) * | 2011-11-11 | 2014-06-25 | Rinat Neuroscience Corp | Anticuerpos especificos para trop-2 y sus usos |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
-
2012
- 2012-11-07 AR ARP120104194A patent/AR088693A1/es unknown
- 2012-11-07 MX MX2014005728A patent/MX2014005728A/es unknown
- 2012-11-07 CN CN201280055208.2A patent/CN104053672A/zh active Pending
- 2012-11-07 WO PCT/IB2012/056234 patent/WO2013068946A2/en not_active Ceased
- 2012-11-07 AU AU2012335205A patent/AU2012335205A1/en not_active Abandoned
- 2012-11-07 PH PH1/2014/500932A patent/PH12014500932A1/en unknown
- 2012-11-07 CA CA2954166A patent/CA2954166A1/en not_active Abandoned
- 2012-11-07 JP JP2014540611A patent/JP5936702B2/ja not_active Expired - Fee Related
- 2012-11-07 HK HK15102314.8A patent/HK1201851A1/xx unknown
- 2012-11-07 EP EP12788646.3A patent/EP2776470A2/en not_active Ceased
- 2012-11-07 BR BR112014011331A patent/BR112014011331A2/pt not_active IP Right Cessation
- 2012-11-07 TW TW101141373A patent/TWI495644B/zh not_active IP Right Cessation
- 2012-11-07 SG SG11201401699WA patent/SG11201401699WA/en unknown
- 2012-11-07 RU RU2014116406/10A patent/RU2014116406A/ru not_active Application Discontinuation
- 2012-11-07 SA SA112330988A patent/SA112330988B1/ar unknown
- 2012-11-07 US US13/670,730 patent/US8871908B2/en not_active Expired - Fee Related
- 2012-11-07 CA CA2854720A patent/CA2854720C/en not_active Expired - Fee Related
- 2012-11-07 KR KR1020147015364A patent/KR20140091040A/ko not_active Ceased
-
2014
- 2014-05-01 IL IL232426A patent/IL232426A0/en unknown
- 2014-05-09 CO CO14100190A patent/CO7010785A2/es unknown
- 2014-05-14 ZA ZA2014/03492A patent/ZA201403492B/en unknown
- 2014-08-15 US US14/460,871 patent/US9399074B2/en not_active Expired - Fee Related
-
2015
- 2015-12-10 JP JP2015240754A patent/JP6157575B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-20 US US15/160,742 patent/US10100114B2/en not_active Expired - Fee Related
-
2017
- 2017-03-14 JP JP2017049125A patent/JP6475277B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-07 US US16/125,032 patent/US11091544B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534233A5 (enExample) | ||
| RU2014116406A (ru) | Антитела, специфичные к trop-2, и их применения | |
| US20240108745A1 (en) | Bioactive substance conjugate, preparation method therefor and use thereof | |
| TWI806895B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| WO2021148003A1 (zh) | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 | |
| RU2016103157A (ru) | Anti-cxcr4 антитела и конъюгаты антитело-лекарство | |
| JP2016505513A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| JP2013056896A5 (enExample) | ||
| JP2011526785A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| JP2013543498A5 (enExample) | ||
| JP2017530722A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| TWI822740B (zh) | 抗her2雙互補位抗體-藥物結合物及使用方法 | |
| JP2017526339A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
| JP2017519759A5 (enExample) | ||
| CA2699834A1 (en) | Improved anti-il-6 receptor antibody | |
| JP2011501656A5 (enExample) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| WO2011036183A3 (de) | Anti-cd33 antikörper und ihre anwendung zum immunotargeting bei der behandlung von cd33-assoziierten erkrankungen | |
| TW201406780A (zh) | 抗－Ｌｙ６Ｅ抗體及免疫結合物及其使用方法 |